Ivy Brain Tumor Center and B≤ ridgeBio Subsidiary QED↕&↔ Therapeutics Announce Collaboration to Adva<₩nce Cancer Research and Trδ∏★eatment Options
The Ivy Brain Tumor Center a¶♦×t Barrow Neurological Institute, tod∞≤ Ωay announced a new collabora✔ π®tion with QED Therapeutics, Inc., a subsidi♣↕ary of BridgeBio Pharma, Inc., (Nasdaq:BBIO) to←π€ investigate the FGF÷•R1-3 tyrosine kinase inhibitor, in∏↓figratinib, for the treatment of g®'lioblastoma (GBM). With the goal ✘¶of addressing unmet medical needs for those∞₩§ affected by malignant brain ca♥₽♠ncer, this collaboration will♥∞• focus on targeting FGFε©¥R (fibroblast growth factor receptor) gen↕™etic alterations that have been shown↔♦β≥ to spur growth in malignant tumors.“Five toγ↑π seven percent of glioblastoma patients’ tumors♥"↔≤ are driven by FGFR signal€✘≤ing,” said Dr. Nader Sanai, director ♣©₹λof the Ivy Brain Tumor Center. “We believe o∑✔ur collaboration with QED Th≈β≤erapeutics will enable us t™≤↓¥o test how FGFR-driven GBM tumors respond •↕π<to infigratinib. If proven effective, we&> then intend to move forward new combined d ©"εrug strategies incorporating thi&★∞s target.”In the preclinic↓÷al studies, the Ivy Center wil¥l employ orthotopically implanted, ¶σ&well-characterized FGFR3 fusion patient-der∑ε¶ived xenograft models. This is intended to alloσ≠φw the team to further explore×≠× the extent to which the drug crosses theγπ≥ blood-brain barrier and what activi₹¥↕ty it has in the brain.“We believe ↔≥♥÷the work we are unde"♦rtaking with the Ivy δ↑↓ Center will provide critical insigh÷¶t to shape our clinical development stratλ✘π$egy for this disease,“ said Susan ÷ Moran, M.D., M.S.C.E©↓., chief medical officer of QED Therapeutics. “Ou≤₹r hope is that infigratinib wi≈±Ωll become the backbone of ne¶✔♥£w combination therapies to treat patients with ♣πglioblastoma.”Infigratiβ↓♥↓nib is an orally administered, FGFR1-3 selective δ♦→tyrosine kinase inhibito↓δr. QED Therapeutics has obs'✘£erved activity that appears t×♠o be meaningful in cl ±≠inical trials for cancers that are driven by e>™rrors in the FGFR genes. These include chemot™∑✔₽herapy-refractory cholangiocarcinoma wλδ±ith FGFR2 fusions and adva✘≤nced urothelial carcinoβφ∏ma with FGFR3 genetic alterations.$λ→÷“The intricacies of the brain hav®✔✘e posed significant challenges for br λain cancer research and the developmenε↔♥t of therapies,” said Gary Li, head&α★ of translational medicine at QED Ther$ε¶apeutics. “We believe collaborating with t£<πhe Ivy Brain Tumor Center will enable us to♠• move swiftly and further translational resea✘∞↓®rch that we hope will unlock the doors ≠<♠¶to effective treatme♣$nt options.”informatioΩδ €n source:pharma focus AsiaThe origiσ÷✔nal link:https:https://www.pharmafocusasia★≥γ©.com/news/ivy-brain-tum↓÷"λor-center-and-bridgebio-subsidiary-qed-therapeutσδ ©ics-announce-collaboration-to-advance-can₽γ≈αcer-research-and-treatment-options20₽→19 Asia-pacific pharma IP Lead★σer Summit:http://en.zenseegroup.com/p/5♥↓™₩10934/will be held in Beijin≈®↑φg on ✘λ₽∏;November 14-15, and will attract ®∞÷more than 500 indust ♦↑ry experts from domestic and foreign pha≈÷∑rmaceutical companies, bio &technology companies, govσ↓εernments, associations, law firm©↓s, intellectual property agents and othe ↑ r companies to attend.Official registratio¥β'n and consultation channels:Contact:AnnPhone: 02♠₽1-65650305Email:Marketing@zenseegroup.comhtt♦→p:/λδforms/view/22113/